153 related articles for article (PubMed ID: 38432396)
1. MEK Inhibition for RASopathy-Associated Hypertrophic Cardiomyopathy: Clinical Application of a Basic Concept.
Chaput D; Andelfinger G
Can J Cardiol; 2024 May; 40(5):789-799. PubMed ID: 38432396
[TBL] [Abstract][Full Text] [Related]
2. New prospectives on treatment opportunities in RASopathies.
Gelb BD; Yohe ME; Wolf C; Andelfinger G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):541-560. PubMed ID: 36533679
[TBL] [Abstract][Full Text] [Related]
3. Mek Inhibitor Reverses Hypertrophic Cardiomyopathy in RIT1 Mutated Noonan Syndrome: For the first time, hypertrophic cardiomyopathy was reversed in Noonan syndrome associated with a RIT1 mutation.
Am J Med Genet A; 2019 Aug; 179(8):1408-1409. PubMed ID: 31355539
[No Abstract] [Full Text] [Related]
4. Nonreentrant atrial tachycardia occurs independently of hypertrophic cardiomyopathy in RASopathy patients.
Levin MD; Saitta SC; Gripp KW; Wenger TL; Ganesh J; Kalish JM; Epstein MR; Smith R; Czosek RJ; Ware SM; Goldenberg P; Myers A; Chatfield KC; Gillespie MJ; Zackai EH; Lin AE
Am J Med Genet A; 2018 Aug; 176(8):1711-1722. PubMed ID: 30055033
[TBL] [Abstract][Full Text] [Related]
5. Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome.
Leegaard A; Gregersen PA; Nielsen TØ; Bjerre JV; Handrup MM
Eur J Med Genet; 2022 Nov; 65(11):104630. PubMed ID: 36184070
[TBL] [Abstract][Full Text] [Related]
6. An Assessment of the Therapeutic Landscape for the Treatment of Heart Disease in the RASopathies.
Yi JS; Perla S; Bennett AM
Cardiovasc Drugs Ther; 2023 Dec; 37(6):1193-1204. PubMed ID: 35156148
[TBL] [Abstract][Full Text] [Related]
7. The RASopathies: from pathogenetics to therapeutics.
Hebron KE; Hernandez ER; Yohe ME
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
[TBL] [Abstract][Full Text] [Related]
8. Malignancy in Noonan syndrome and related disorders.
Smpokou P; Zand DJ; Rosenbaum KN; Summar ML
Clin Genet; 2015 Dec; 88(6):516-22. PubMed ID: 25683281
[TBL] [Abstract][Full Text] [Related]
9. Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition.
Andelfinger G; Marquis C; Raboisson MJ; Théoret Y; Waldmüller S; Wiegand G; Gelb BD; Zenker M; Delrue MA; Hofbeck M
J Am Coll Cardiol; 2019 May; 73(17):2237-2239. PubMed ID: 31047013
[No Abstract] [Full Text] [Related]
10. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
[TBL] [Abstract][Full Text] [Related]
11. Advancing RAS/RASopathy therapies: An NCI-sponsored intramural and extramural collaboration for the study of RASopathies.
Gross AM; Frone M; Gripp KW; Gelb BD; Schoyer L; Schill L; Stronach B; Biesecker LG; Esposito D; Hernandez ER; Legius E; Loh ML; Martin S; Morrison DK; Rauen KA; Wolters PL; Zand D; McCormick F; Savage SA; Stewart DR; Widemann BC; Yohe ME
Am J Med Genet A; 2020 Apr; 182(4):866-876. PubMed ID: 31913576
[TBL] [Abstract][Full Text] [Related]
12. Dermatological manifestations, management, and care in RASopathies.
Kavamura MI; Leoni C; Neri G
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):452-458. PubMed ID: 36541891
[TBL] [Abstract][Full Text] [Related]
13. Severe Lymphatic Disorder and Multifocal Atrial Tachycardia Treated with Trametinib in a Patient with Noonan Syndrome and SOS1 Mutation.
Lioncino M; Fusco A; Monda E; Colonna D; Sibilio M; Caiazza M; Magri D; Borrelli AC; D'Onofrio B; Mazzella ML; Colantuono R; Arienzo MR; Sarubbi B; Russo MG; Chello G; Limongelli G
Genes (Basel); 2022 Aug; 13(9):. PubMed ID: 36140671
[TBL] [Abstract][Full Text] [Related]
14. Objective studies of the face of Noonan, Cardio-facio-cutaneous, and Costello syndromes: A comparison of three disorders of the Ras/MAPK signaling pathway.
Allanson JE
Am J Med Genet A; 2016 Oct; 170(10):2570-7. PubMed ID: 27155212
[TBL] [Abstract][Full Text] [Related]
15. Clinical overview on RASopathies.
Zenker M
Am J Med Genet C Semin Med Genet; 2022 Dec; 190(4):414-424. PubMed ID: 36428239
[TBL] [Abstract][Full Text] [Related]
16. Autism traits in the RASopathies.
Adviento B; Corbin IL; Widjaja F; Desachy G; Enrique N; Rosser T; Risi S; Marco EJ; Hendren RL; Bearden CE; Rauen KA; Weiss LA
J Med Genet; 2014 Jan; 51(1):10-20. PubMed ID: 24101678
[TBL] [Abstract][Full Text] [Related]
17. Clinical Presentation and Natural History of Hypertrophic Cardiomyopathy in RASopathies.
Calcagni G; Adorisio R; Martinelli S; Grutter G; Baban A; Versacci P; Digilio MC; Drago F; Gelb BD; Tartaglia M; Marino B
Heart Fail Clin; 2018 Apr; 14(2):225-235. PubMed ID: 29525650
[TBL] [Abstract][Full Text] [Related]
18. Genetic landscape of RASopathies in Chinese: Three decades' experience in Hong Kong.
Yu KPT; Luk HM; Leung GKC; Mak CCY; Cheng SSW; Hau EWL; Chan DKH; Lam STS; Tong TMF; Chung BHY; Lo IFM
Am J Med Genet C Semin Med Genet; 2019 Jun; 181(2):208-217. PubMed ID: 30896080
[TBL] [Abstract][Full Text] [Related]
19. Cardiac manifestations and gene mutations of patients with RASopathies in Taiwan.
Lee CL; Tan LTH; Lin HY; Hwu WL; Lee NC; Chien YH; Chuang CK; Wu MH; Wang JK; Chu SY; Lin JL; Lo FS; Su PH; Hsu CC; Ko YY; Chen MR; Chiu HC; Lin SP
Am J Med Genet A; 2020 Feb; 182(2):357-364. PubMed ID: 31837205
[TBL] [Abstract][Full Text] [Related]
20. The seventh international RASopathies symposium: Pathways to a cure-expanding knowledge, enhancing research, and therapeutic discovery.
Kontaridis MI; Roberts AE; Schill L; Schoyer L; Stronach B; Andelfinger G; Aoki Y; Axelrad ME; Bakker A; Bennett AM; Broniscer A; Castel P; Chang CA; Cyganek L; Das TK; den Hertog J; Galperin E; Garg S; Gelb BD; Gordon K; Green T; Gripp KW; Itkin M; Kiuru M; Korf BR; Livingstone JR; López-Juárez A; Magoulas PL; Mansour S; Milner T; Parker E; Pierpont EI; Plouffe K; Rauen KA; Shankar SP; Smith SB; Stevenson DA; Tartaglia M; Van R; Wagner ME; Ware SM; Zenker M
Am J Med Genet A; 2022 Jun; 188(6):1915-1927. PubMed ID: 35266292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
